Related Experiment Video

Updated: Sep 26, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity

Lan Zhou1, Naili An, Rex C Haydon

  • 1Department of Surgery, The University of Chicago Medical Center, 5841 South Maryland Avenue, MC3079, Chicago, IL 60637, USA.

Cancer Letters
|April 23, 2003
PubMed

Insights

The tyrosine kinase inhibitor STI-571 suppresses beta-catenin signaling activity and colon cancer cell proliferation. This suggests targeting beta-catenin signaling with STI-571 could be a novel cancer treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Beta-catenin is a key Wnt pathway transducer involved in development and cellular processes.
  • Aberrant beta-catenin signaling is implicated in various human cancers.
  • Understanding regulatory mechanisms of beta-catenin is crucial for cancer therapy.

Purpose of the Study:

  • To investigate the effect of tyrosine kinase inhibitor STI-571 on beta-catenin signaling.
  • To determine if STI-571 can inhibit cancer cell proliferation.
  • To explore the role of tyrosine phosphorylation in beta-catenin regulation.

Main Methods:

  • Assessed STI-571's impact on constitutive and Wnt1-induced beta-catenin signaling in colon cancer cells and other cell lines (HOS, HTB-94, HEK 293).
  • Evaluated STI-571's effect on human colon cancer cell proliferation.
  • Utilized a GAL4-beta-catenin heterologous transcription system to study Wnt1-mediated activation inhibition.

Main Results:

  • STI-571 effectively inhibited constitutive beta-catenin signaling in colon cancer cells.
  • STI-571 suppressed Wnt1-induced beta-catenin activation in multiple cell lines.
  • STI-571 demonstrated significant suppression of human colon cancer cell proliferation.
  • Wnt1-mediated activation of the GAL4-beta-catenin system was inhibited by STI-571.

Conclusions:

  • Tyrosine phosphorylation appears to be a critical regulator of beta-catenin signaling activity.
  • STI-571's inhibition of beta-catenin signaling offers a potential therapeutic target for various human cancers.
  • Further exploration of STI-571 as an alternative/adjuvant cancer treatment is warranted.

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: